Are there other companies developing our technology?

There are no other companies that utilize our electromagnetic technology against the cognitive impairment of Alzheimer’s Disease. There are several academic institutions in Europe utilizing very different electromagnetic approaches against AD that have not, however, been shown to affect the AD process. Indirect competitors include those testing whether transcranial Magnetic Stimulation (tMS) can treat AD cognitive impairment. However, tMS is a different neuromodulatory approach that simply provides generalized stimulation/inhibition effects on neuronal activity, which has not been shown to affect the AD process. Another neuromodulatory approach against AD is deep brain stimulation (DBS), wherein electrodes implanted deep into the human brain provide stimulation to a limited brain region; DBS also has not been shown to affect the AD process. The largest and most recent clinical trials testing tMS or DBS in AD subjects have found minimal or no cognitive benefit following long-term treatment.

Have your pre-clinical results been independently confirmed by other laboratories?

Yes. Following our initial 2010 publication, three independent laboratories published results in 2013, 2015, and 2018 showing that similar electromagnetic treatment to Alzheimer’s mice can provide cognitive benefit and/or substantially decrease Alzheimer’s neuropathology. In addition, our own studies were performed in collaboration with seven independent laboratories, all of which were blind to which mice received treatment and which ones did not.

Is this technology safe for human therapeutic use?

There have been many human studies investigating safety of the electromagnetic technology that we are utilizing. All recent studies, including extensive analysis by the National Institute of Environmental Health Sciences (NIEHS), have concluded that there are no health or safety risks associated with long-term exposure to the electromagnetic parameters we have been utilizing clinically. Our extensive safety evaluations of daily treatment (for up to 8 months) in AD mice showed no deleterious effects of TEMT on brain temperature, brain morphology, immune function, brain protein oxidation, brain antioxidant enzymes, or peripheral DNA oxidation. Nonetheless, our technology has only now been tested on humans, with safety results from NeuroEM Therapeutics’ Phase I clinical trial in AD patients to be made public shortly.

It is important to recognize that NeuroEM’s technology is being utilized in a specialized head device that utilizes many unique electromagnetic emitters. The result is full brain treatment that, although complying with FDA/FCC regulations, delivers global electromagnetic treatment to the human brain.

When will NeuroEM’s head device be commercially available to treat AD?

It is anticipated that, with adequate funding and adherence to our clinical timeline, our TEMT medical device for preventing/treating AD could be available for commercialization in late 2021/2022.

When will the results of NeuroEM’s Phase I clinical trial in AD patients be available to the public?

The results of NeuroEM’s just-completed Phase I clinical trial should be made public in June or July 2019.

How can I or my loved one with AD participate in a clinical trial involving treatment with Transcranial Electromagnetic Treatment (TEMT)?

The clinical location(s) for NeuroEM’s Pivotal clinical trial in AD patients will be announced on this website prior to the beginning of patient recruitment for that trial.